Study guide
12.1 Neurological Acute, Chronic, and Late Effects
Certified Pediatric Hematology Oncology Nurse CPHON®
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy
2 Care Continuum
2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship
3 Leukemias and Lymphomas
3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas
4 CNS, Neuroblastoma, and Renal Tumors
4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors
5 Sarcomas and Other Solid Tumors
5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors
6 Hematologic Disorders
6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure
7 Pathophysiology, Genetics, and Diagnostics
7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis
8 Clinical Trials and Professional Performance
8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education
9 Chemotherapy and Biotherapy
9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy
10 Immunotherapy, Cellular Therapy, and Radiation
10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam
11 HSCT, Surgery, Transfusion, and Coagulation Therapy
11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
12 Neurologic, Respiratory, and Cardiovascular Effects
12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects
13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects
13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects
14 Endocrine, Hematologic, Immunologic, and Sensory Effects
14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects
15 Pain, Sleep, Fatigue, and Mental Health
15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects
16 Supportive Care
16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care
17 Infectious and Gastrointestinal Emergencies
17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction
18 Metabolic Emergencies
18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome
19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome
19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
20 Sickle Cell and Hemostasis Emergencies
20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed
21 Cardiopulmonary Emergencies
21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias
22 Neurologic and Infusion Emergencies
22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation
23 Family, Caregivers, and Social Integration
23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment
24 Development, Grief, Culture, and Community Resources
24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources
12.1 Neurological Acute, Chronic, and Late Effects
Key Takeaways Explain This Topic AI
Vincristine neuropathy presents as foot drop, constipation or ileus, and jaw pain; start a bowel regimen, use fall precautions, and report new deficits so the protocol can hold or reduce the vinca.
Methotrexate leukoencephalopathy (intrathecal or high-dose intravenous, worse with cranial radiation) can be acute and stroke-like or a chronic white-matter injury; ifosfamide encephalopathy is an infusion-window confusional state treated by stopping the drug and giving methylene blue as ordered.
Steroid myopathy is proximal weakness and mood lability (dexamethasone often harsher than prednisone); do not stop corticosteroids abruptly.
Posterior fossa syndrome (mutism, ataxia, emotional lability, aspiration risk) appears one to two days after medulloblastoma or other vermian resection; radiation somnolence is delayed sleepiness about three to eight weeks after cranial radiation and is not rising intracranial pressure until proven otherwise.
Neurocognitive late effects after CNS-directed therapy cluster on attention, processing speed, and working memory; arrange neuropsychological testing and a 504 plan or individualized education program (IEP). Hearing is a cochlear and eighth-nerve overlap taught in the otologic chapter.
Last updated: August 2026
CPHON Test Content Outline (TCO) IV.A.1 tests neurologic acute, chronic, and late effects of chemotherapy, radiation, corticosteroids, and central-nervous-system (CNS) surgery. It is not the emergency chapter. Full algorithms for increased intracranial pressure (ICP) , status epilepticus, and posterior reversible encephalopathy syndrome (PRES) live later. Here the nurse names the exposure, watches the function that is failing, and keeps the child from falling or aspirating while the team holds, reduces, or rescues the drug.
A 4-year-old on acute lymphoblastic leukemia (ALL) induction who will not climb stairs, a 12-year-old who becomes confused during ifosfamide , and a 7-year-old who stops speaking two days after medulloblastoma resection are all neurologic-effect patients. Compare them with last week's developmental baseline , not with an adult Glasgow script and not with "chemo fatigue."
Vincristine neuropathy
Vincristine binds tubulin and injures long axons. Three maps matter at the chairside:
Peripheral motor and sensory: lost Achilles reflexes, foot drop , a steppage gait, difficulty climbing stairs or rising from the floor, stocking-glove paresthesias. A preschooler may simply refuse to walk.
Autonomic: constipation that progresses to ileus , abdominal distention, urinary retention. Constipation after vincristine is a neurologic effect, not a dietary inconvenience.
Cranial: jaw pain during or after the dose, ptosis, hoarseness, vocal-cord paresis.
Start a bowel regimen (polyethylene glycol, senna as ordered) the day vincristine starts, not after three days without stool. Institute fall precautions . Involve physical therapy; an ankle-foot orthosis may be needed when foot drop appears. Report new foot drop, ileus, or jaw pain so the protocol can hold or reduce vincristine. Do not keep hanging the Friday dose because "everyone gets neuropathy." Recovery can take months and may be incomplete—that is a chronic effect. Hearing loss is a cochlear and eighth-cranial-nerve problem taught in the otologic chapter; mention it here only so you do not mislabel vincristine jaw pain as ototoxicity or skip audiology when platinum or cochlear radiation is also on the roadmap.
Methotrexate leukoencephalopathy and ifosfamide encephalopathy
Methotrexate given intrathecally (IT) or as high-dose intravenous therapy can injure white matter. Acute leukoencephalopathy appears during or shortly after a dose: stroke-like weakness, aphasia, seizures, or an abrupt change in school-age speech. Many episodes are transient; they are still not "attention-seeking." Hold further methotrexate, obtain urgent imaging as ordered, use seizure precautions, and continue serial neurologic checks. Subacute and chronic leukoencephalopathy —especially after methotrexate plus cranial radiation —leaves lasting white-matter change, processing-speed loss, and sometimes a stepwise cognitive decline. An 8-year-old who was bilingual and now searches for words weeks after high-dose methotrexate needs a neurologic workup, not a pep talk.
Ifosfamide encephalopathy is a different clock. The chloroacetaldehyde metabolite causes somnolence, confusion, hallucinations, cerebellar signs, or seizures during or within hours of the infusion. Renal impairment, prior platinum, and low albumin raise risk. Stop the remaining ifosfamide, protect the airway, and give methylene blue when the team orders it. Do not attribute new confusion on an ifosfamide day to hospital sleep or to an opioid dose that has not changed. Rising ICP can look sleepy too: a new unequal pupil, Cushing triad, or a falling Glasgow Coma Scale (GCS) is an emergency-chapter problem, not methylene blue by habit.
Steroid myopathy and mood
Dexamethasone and prednisone cause proximal myopathy and mood lability . Dexamethasone is often harsher on both. A 5-year-old on ALL induction who cannot rise from the toilet, who rages at night, and who has not slept is not "noncompliant." Teach families the mood window, pad the environment, do not force competitive physical education, and involve physical therapy. Do not stop corticosteroids abruptly—adrenal insufficiency is a separate endocrine trap. Psychosis and severe insomnia are reportable, not a reason to skip the next protocol day without the team.
Posterior fossa syndrome and radiation somnolence
After medulloblastoma or other midline posterior-fossa resection, posterior fossa syndrome (cerebellar mutism) often declares itself one to two days later . The child who spoke after anesthesia becomes mute or severely dysarthric , ataxic , hypotonic, emotionally labile , and may stop swallowing. This is not emergence delirium and not stubbornness. Protect the airway , treat aspiration risk, keep the child nothing-by-mouth until swallow is assessed, and start speech-language pathology, occupational therapy, and physical therapy. Tell the family that recovery takes weeks to months and may be incomplete. That teaching is TCO IV.A.1 symptom management; the tumor-staging chapter does not replace it.
Radiation somnolence syndrome appears about three to eight weeks after cranial radiation : profound sleepiness, anorexia, irritability, and sometimes low-grade fever. It is usually self-limited over days to a few weeks. Support hydration and school absence. Distinguish it from recurrence, meningitis, and rising ICP . Morning vomiting plus a new pupil change or a falling GCS is not somnolence syndrome. Escalate those findings to the emergency ICP pathway rather than coaching a nap.
- Effect Typical trigger Clock Nursing focus
- Vincristine neuropathy Vinca during therapy Acute; may become chronic Bowel regimen, falls, hold or reduce
Methotrexate leukoencephalopathy IT or high-dose MTX ± cranial RT Acute stroke-like; chronic white matter Neuro checks, hold MTX, seizure precautions
Ifosfamide encephalopathy During or hours after infusion Acute Stop drug; methylene blue as ordered
Steroid myopathy and mood Dexamethasone or prednisone Acute to subacute Proximal weakness, safety, no abrupt stop
Posterior fossa syndrome 1–2 days after vermian surgery Subacute postoperative Aspiration, mutism, family timeline
- Radiation somnolence About 3–8 weeks after cranial RT Subacute Support; rule out ICP and infection
- Neurocognitive late effects Young age, CNS-directed therapy Late (school years) Neuropsychology, 504 or IEP
- Assessment, safety, and neurocognitive late effects
Serial assessment is the intervention. Use the GCS (eye, verbal, motor, with pediatric verbal modifications for preverbal children), pupil size and reactivity, and a developmental baseline : what could this child do last clinic visit? A toddler who stops using two-word phrases is a neurologic change even if the GCS is still 15. Safety is falls (neuropathy, myopathy, ataxia) and aspiration (mutism, cranial-nerve weakness, encephalopathy). Seizure precautions belong whenever leukoencephalopathy, ifosfamide, or a fresh posterior fossa is in play.
Neurocognitive late effects after CNS-directed therapy—IT methotrexate, high-dose methotrexate, cranial radiation, especially at a young age —cluster on attention, processing speed, and working memory . Full-scale IQ can look acceptable while the child cannot finish a timed test. Arrange neuropsychological testing and school supports: a 504 plan or individualized education program (IEP) with extra time, reduced load, and seating that helps attention. Do not wait for the child to fail a grade. Cochlear hearing loss is an overlap, not the whole story; send audiology rather than blaming "not listening" solely on cognition.
A blown pupil, Cushing triad, or hypertensive encephalopathy with visual change is not an IEP meeting. Signpost ICP, seizures, and PRES to their emergency sections and keep this chapter on the chronic watch, the hold, and the school plan.